Trial Outcomes & Findings for Evaluation of PillCam® Express Capsule Endoscopy Delivery System (NCT NCT01088646)

NCT ID: NCT01088646

Last Updated: 2020-10-22

Results Overview

The number of capsules that successfully were in the duodenum as indicated by video images

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

25 participants

Primary outcome timeframe

up to 7 days

Results posted on

2020-10-22

Participant Flow

3 hospital sites

Participant milestones

Participant milestones
Measure
PillCam Express Capsule Delivery System
PillCam® Express Capsule Endoscopy Delivery System was used in conjunction with the endoscope to introduce a PillCam® SB capsule into the proximal duodenum. After the capsule was released in the designated location, a standard of care upper GI endoscopy was performed.
Overall Study
STARTED
25
Overall Study
COMPLETED
25
Overall Study
NOT COMPLETED
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Evaluation of PillCam® Express Capsule Endoscopy Delivery System

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
PillCam Express Capsule Delivery System
n=25 Participants
PillCam® Express Capsule Endoscopy Delivery System was used in conjunction with the endoscope to introduce a PillCam® SB capsule into the proximal duodenum. After the capsule was released in the designated location, a standard of care upper GI endoscopy was performed.
Age, Categorical
<=18 years
0 Participants
n=99 Participants
Age, Categorical
Between 18 and 65 years
20 Participants
n=99 Participants
Age, Categorical
>=65 years
5 Participants
n=99 Participants
Age, Continuous
51 years
STANDARD_DEVIATION 18.3 • n=99 Participants
Sex: Female, Male
Female
19 Participants
n=99 Participants
Sex: Female, Male
Male
6 Participants
n=99 Participants
Region of Enrollment
United States
25 participants
n=99 Participants

PRIMARY outcome

Timeframe: up to 7 days

The number of capsules that successfully were in the duodenum as indicated by video images

Outcome measures

Outcome measures
Measure
Pillcam Express Capsule Delivery System
n=25 Participants
The delivery system is comprised of three parts: a catheter, a syringe and a capsule holder.
Number of Participants With Successful Capsule Placement Into the Duodenum Using Capsule Delivery System
25 participants

SECONDARY outcome

Timeframe: 7 days

Population: Physicians completed questionnaires for each of the 25 subjects. The questions were divided to two: physicians assessment A where 'YES' is associated with a smooth procedure (4 questions x 25 subjects = 100 Y/N assessments) and physicians B where 'no' is associated with smooth procedure (6 questions x 25 subjects = 150 Y/N assessment).

The physician was required to assess the ease of use while answering a designated questionnaire. In addition, qualitative analysis was reformed with regard to all the open questions.

Outcome measures

Outcome measures
Measure
Pillcam Express Capsule Delivery System
n=250 Y/N questions
The delivery system is comprised of three parts: a catheter, a syringe and a capsule holder.
Physician's Subjective Assessment of the Ease of Capsule Placement
Physician Assessment A
94 assessments
Physician's Subjective Assessment of the Ease of Capsule Placement
Physician Assessment B
126 assessments

Adverse Events

PillCam Express Capsule Delivery System

Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
PillCam Express Capsule Delivery System
n=25 participants at risk
PillCam® Express Capsule Endoscopy Delivery System was used in conjunction with the endoscope to introduce a PillCam® SB capsule into the proximal duodenum. After the capsule was released in the designated location, a standard of care upper GI endoscopy was performed.
Gastrointestinal disorders
capsule failed to deploy in first attempt
4.0%
1/25 • Number of events 1 • Adverse Event information was collected from screening (up to -14 day prior to procedure) through follow up phone contact at 5-10 days after the procedure

Additional Information

Hilla Debby/Director of clinical affairs

Givenimaging

Phone: 97249097774

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place